Related Experiment Videos
[In vitro antibacterial activity of cefpirome: a new cephalosporin; results of a multicenter study]
C J Soussy1, M Chanal, E Derlot
1Service de Bactériologie, Hôpital Henri Mondor, Créteil, France.
Abstract:
The in vitro activity of cefpirome, a new injectable cephalosporin was studied against 1,082 clinical isolates in a multicentre study. Minimum inhibitory concentrations were determined using an agar dilution method. Cefpirome was active against Enterobacteriaceae. On naturally non-producing beta-lactamase species, cefpirome was active on most of the strains with MICs < or = 0.5 mg/l, including strains producing an acquired penicillinase: E. coli 0.03-0.06, P. mirabilis 0.06-0.12, Salmonella spp. 0.06-0.06, Shigella spp. 0.016-0.03. MICs of K. pneumoniae (0.06-4) ranged from 0.016 to 32:MICs were high against expanded-spectrum betalactamase producers strains. Against species producing cephalosporinase, cefpirome was also active on most of the strains with MICs < or = 0.5: E. cloacae 0.06-2, Citrobacter spp. 0.03-1, S. marcescens 0.06-0.5, P. indol + 0.06-0.25, P. stuartii 0.12-0.5. Cefpirome was less active on Pseudomonas aeruginosa, (8-32) and on A. baumanii (16-32). MICs of cefpirome were low against Haemophilus spp. betalactamase producing or not (0.01-0.03) and M. catarrhalis (0.6-4). Activity of cefpirome on methicillin-sensitive staphylococci, was higher than other third generation cephalosporins (0.25-2) comparable to that of cephalotin and cefamandol. Methicillin-resistant strains should be considered as resistant. Pneumococci (0.01-0.03), except for penicillin-R strains, and streptococci A, B, C, G (0.01-0.06) were very susceptible. Enterococci were of low sensitivity or resistant. Among anaerobes, C. perfringens appeared often susceptible, and Bacteroides spp. resistant.
Insights
Cefpirome, a new cephalosporin, shows broad in vitro activity against many common bacterial pathogens, including Enterobacteriaceae and Gram-positive cocci. However, resistance was noted in certain resistant strains and specific Gram-negative bacteria like Pseudomonas aeruginosa.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- The emergence of antibiotic resistance necessitates the continuous evaluation of novel antimicrobial agents.
- Cephalosporins are a critical class of antibiotics used to treat a wide range of bacterial infections.
Purpose of the Study:
- To assess the in vitro antimicrobial activity of cefpirome against a large collection of clinical bacterial isolates.
- To determine the spectrum of activity and potential clinical utility of this new cephalosporin.
Main Methods:
- A multicentre study involving 1,082 clinical isolates.
- Minimum inhibitory concentrations (MICs) were determined using a standardized agar dilution method.
Main Results:
- Cefpirome demonstrated excellent activity against most Enterobacteriaceae, including strains producing acquired penicillinases.
- The agent was active against many cephalosporinase-producing species, but less so against Pseudomonas aeruginosa and Acinetobacter baumannii.
- Cefpirome showed potent activity against Streptococcus pneumoniae and other streptococci, and good activity against methicillin-susceptible staphylococci.
Conclusions:
- Cefpirome exhibits a broad spectrum of in vitro activity against a variety of clinically relevant bacteria.
- Its efficacy against Gram-positive cocci, including some resistant strains, is notable, though resistance in certain Gram-negative pathogens warrants consideration.